Indaptus Therapeutics Bolsa (NASDAQ: INDP)

Últimas noticias sobre Indaptus Therapeutics (NASDAQ:INDP) Bolsa

Indaptus Therapeutics

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics Inc

WIIM

IBIO

iBio shares ae trading higher after the company announced it will host a conference call to review its advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.

<p>Cidara Therapeutics, Inc. ("Cidara") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>), a biotechnology company using its proprietary Cloudbreak&#xAE; platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250.0 million of shares of its common stock. All of the shares are being offered by Cidara. In connection with the proposed offering, Cidara expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.</p>


News

Offerings

CDTX

Cidara Therapeutics Plans To Commence Underwritten Public Offering To Issue And Sell $250M Of Shares

EHLD

EuroHoldings shares are trading higher after the company announced certain shareholders associated with the Pittas family entered into a Stock Purchase Agreement and sold 51.04% of its outstanding shares to Marla Investments.

<p><a href="https://www.bloomberg.com/news/articles/2025-06-23/meta-held-deal-talks-with-startup-runway-in-ai-recruiting-push?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-06-23/meta-held-deal-talks-with-startup-runway-in-ai-recruiting-push?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-06-23/meta-held-deal-talks-with-startup-runway-in-ai-recruiting-push?srnd=homepage-americas</a></p>


'Meta Held Deal Talks With Startup Runway In AI Recruiting Push' -Bloomberg

<p>Natural Alternatives International, Inc. ("NAI") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced the execution of an amended credit facility with Wells Fargo Bank, NA ("Wells Fargo"). This amendment modifies the current facility extending the term of the agreement to December 31, 2026 and modifies the borrowing capacity to $10 million.</p>


NAII

Natural Alternatives Executes Amended Credit Facility With Wells Fargo Bank; Modifies Borrowing Capacity To $10M

<p>Crypto markets opened the week in the green, buoyed by <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46045741/rich-dad-poor-dad-author-robert-kiyosaki-warns-of-global-debt-collapse-urges-buying-gold-silver-bitcoin">renewed institutional interest </a>and strong ETF inflows. As geopolitical tensions ease and oil prices stabilize, risk-on sentiment is returning, fueling a rebound across major digital assets.</p>
<p><figure class="wp-block-table"><br />
<table class="has-fixed-layout">
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Ticker</strong></td>
<td><strong>Price</strong></td>
</tr>
<tr>
<td><strong>Bitcoin</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$102,901.84</td>
</tr>
<tr>
<td><strong>Ethereum</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,299.19</td>
</tr>
<tr>
<td><strong>Solana</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$138.88</td>
</tr>
<tr>
<td><strong>XRP</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.05</td>
</tr>
<tr>
<td><strong>Dogecoin</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1569</td>
</tr>
<tr>
<td><strong>Shiba Inu</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001110</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Notable Statistics:</strong></p>
<ul class="wp-block-list">
<li>IntoTheBlock data shows large transaction volume increasing by 53.9% and daily active addresses falling by 10%. Transactions greater than $100,000 are up from 7,508 to 9,188 in a single day. </li>
<li>CoinGlass data reports that 133,867 traders were liquidated in the past 24 hours, with the total liquidations at $440.14 million.</li>
</ul>
<p><strong>Notable Developments:</strong></p>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46053846/will-bitcoin-hit-new-all-time-highs-after-dip-under-100k-heres-what-new-poll-predicts">Will Bitcoin Hit New All-Time Highs After Dip Under $100K? Here&#8217;s What New Poll Predicts</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46050168/investors-poured-billions-into-bitcoin-and-ethereum-even-as-iran-israel-tensions-escalated">Investors Poured Billions Into Bitcoin And Ethereum Even As Iran-Israel Tensions Escalated</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46051809/veda-secures-18m-to-scale-defi-vaults-across-chains-eyes-centralized-exchange-partnership">Veda Secures $18M To Scale DeFi Vaults Across Chains, Eyes Centralized Exchange Partnership</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46045511/strategys-michael-saylor-signals-no-halt-to-bitcoin-purchases-despite-plunge-below-100000-peter-schiff-asks-who-else-is-buying-the-dip">Strategy&#8217;s Michael Saylor Signals No Halt To Bitcoin Purchases Despite Plunge Below $100,000: Peter Schiff Asks Who Else Is Buying The Dip</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46055637/fiserv-paypal-expand-partnership-to-advance-stablecoin-payments">Fiserv, PayPal Expand Partnership To Advance Stablecoin Payments</a></li>
<li><a href="https://www.benzinga.com/m-a/25/06/46052819/anthony-pompliano-unveils-procap-financial-1b-bitcoin-treasury">Anthony Pompliano Unveils ProCap Financial With $1B Bitcoin Treasury After $750M Fundraise</a></li>
</ul>
<p><strong>Top Gainers:</strong></p>
<p><figure class="wp-block-table"><br />
<table class="has-fixed-layout">
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Ticker</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;</strong></td>
</tr>
<tr>
<td><strong>SPX6900</strong></td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SPX</a>)</td>
<td>$1.18</td>
</tr>
<tr>
<td><strong>Sonic</strong></td>
<td>(CRYPTO: S)</td>
<td>$0.2941</td>
</tr>
<tr>
<td><strong>Fartcoin</strong></td>
<td>(CRYPTO: FARTCOIN)</td>
<td>$0.9971</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Trader Notes: </strong>Crypto trader Blockchainedbb <a href="https://x.com/blockchainedbb/status/1937219375162867839">remains</a> on the sidelines, awaiting a decisive daily close before taking action. According to him, a close below $101,000 could trigger a liquidity sweep, potentially followed by a mid-wick sweep. He warns traders against entering prematurely to avoid being caught in choppy price action and suffering emotional fatigue from holding losing positions.</p>
<p>His strategy: wait for clear confirmations on the 4-hour or daily timeframes. Some market ranges, he emphasizes, are better left untouched.</p>
<p>Another trader Skew <a href="https://x.com/52kskew/status/1937213385625731402">marks</a> $103,000 as the battleground level for Bitcoin, describing it as former support turned supply. A close above or below this level will help define the short-term trend direction, making today's close critical.</p>
<p>Doctor Profit highlights Bitcoin&#8217;s nearing reclaim of the key &#8220;golden line&#8221; level. A daily close above this threshold would invalidate the current bearish thesis. He has moved his stop loss to the entry at $103,300, minimizing risk while staying in the short position for now. If the price hits that level, he'll exit the trade.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> almost regained the golden line, close daily candle above would cancel all bearish thesis. Placing stop loss at entry $103,300 to avoid any loss. Keeps short open but its going to close if touching entry. <a href="https://t.co/VfXeACLMsr">pic.twitter.com/VfXeACLMsr</a></p>
<p>&mdash; Doctor Profit &#x1f1e8;&#x1f1ed; (@DrProfitCrypto) <a href="https://twitter.com/DrProfitCrypto/status/1937219372256264219?ref_src=twsrc%5Etfw">June 23, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Castillo Trading <a href="https://x.com/CastilloTrading/status/1937213824077299839">focuses </a>on Bitcoin's naked Point of Control (nPOC) at $99,184, a significant volume-based level. The nPOC was successfully retested, and he notes the current market structure is unfolding as expected with the retest potentially setting the stage for the next major move.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46049663/bitcoins-weekend-drop-could-be-bullish-trader-eyes-97000-as-key-buy-zone">Bitcoin&#8217;s Weekend Drop Could Be Bullish — Trader Eyes $97,000 As Key Buy Zone</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

$DOGE

$ETH

$SHIB

$SOL

$SPX

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Rebound As Week Opens - $103,000 Emerges As Key Battleground

<p><i>Review of promising Myostatin and Activin E antibody data</i></p>
<p><i>iBio to announce 3rd target in Astral Bio Collaboration</i></p>
<p><i>Conference call Tuesday, June 24 at 8:30 a.m. ET</i></p>
<p><a href="https://www.globenewswire.com/Tracker?data=AArIgDBHU7xoOYsPhyFqgHmp9hnOyBxFIwReOocYsVhUsyHdt0HELqAT5nkY2-NvTOFKZysrKo5vuluNqWWsolH1eAUYPlVzHJMQs2AwFS_S363D_8gFOxCtAYL6rPoBVeryWdyrYE6IbE7PstmEnmq1lgU9TGQ6kDcs6TY-mSO_X9V82QlcMVrjZNegNxBGpArYzANbikBKvZqlS_IIFEMfyk2aQX1RInx5boJhrN6W4vDaAZMlJ-Gka7y94HkApfWSLgru2lP-1h9LJRfDqsdkJLNTFzd9871KOUrlkJeZdFz6zB7kvrcSNgrUDXf19zP9kywg-EEvmd-QwPeDT7D98Sd7C_98qPc0Cgo_pyB1XUAEg7vVTjwG-CFszDbuyBa0wo6kcukWdu87wPOMoF42mqXaoAPnmU6A3U_3Nzg=">iBio, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.<br /><br /><br /><br />Martin Brenner, DVM, Ph.D., iBio's CEO and Chief Scientific Officer, will outline how iBio is pioneering the next generation of antibody medicines—targeted, longer-lasting, and potentially better tolerated therapies with more sustainable efficacy. Dr. Brenner will present a strategic overview of the obesity strategy, including details on their long acting Myostatin, <a href="https://www.globenewswire.com/Tracker?data=DUeYYeu_KTZc3S5Lr7e0MEImgLOjkEenZSVPu9vdxbKg9ysh7udoahEdmXfDiQSbapGzX0LkUy9wO_-6lmUguFGaniGhmtGBUuj8flh81RkZx6j7xjmoSuWusuwjBrmjU33jqQT2fSeNHKW-sBlj4OojSLfq4cX7dt-BVsQyv9SB9RrB9iBlByiJwGviyLWN49WQNBhSJlmLNhtKxYDwIg==">IBIO-600</a>, new preclinical data on <a href="https://www.globenewswire.com/Tracker?data=X8miJpcOvA9ijW6OUSgvClZSr5OVJo__yQdOQmPwqO0gN7ShWyZK2NCZiwwM11uR3eK5_wafYdyIvO1GQ6lnWPlbKY2VnTTgHyFd2Gz-aiyIgUNOh-MlVVePTma85YmrCEX7Fhio6WNS9Qh-sc5PgNUxsj89wqcVfUO9YqSO2atCm4eGDx7FHFWfdXJLMb0CXJbRlcjweP8_cr9znTRUyg==">Activin E</a> and, more safe and effective treatment options.<br /><br /><br /><br />The webcast of the live call may be accessed on the Investors section of the iBio website at <a href="https://www.globenewswire.com/Tracker?data=RlMXqtQRbFXTb3NRFmKX1uY-9KEOztuLOayq3Po1ZRsTjefAYQqS9vXyTuam6VR0CkCeSdvdReFwqKsg6DhoUE3-W8xVxbfhxFafgsXrMXBkxCGL6wX23Gj-9fzHIqj0tyzGOp86jg-pt0WW-WnCrw==">ir.ibioinc.com/news-events/ir-calendar</a>. A replay of the webcast will be available on the iBio website for approximately 60 days following the presentation.<br /><br />&nbsp;</p>


Biotech

General

ibio Announces It Will Host  Conference Call On Tuesday, June 24, At 8:30 A.M. EST To Review Its Latest Advances In Obesity And Cardiometabolic Disease Treatments And Announce A Third Target In The Astralbio Collaboration In Addition To Myostatin And Activin E

Management

UDR Appoints Dave Bragg As CFO; Succeeds Joe Fisher

PLYM

Plymouth Industrial REIT Acquires 1.95M Sq Ft Portfolio Of Industrial Properties Across Columbus, Cincinnati, And Cleveland For Total Purchase Price Of $193M

Buybacks

Alset Authorizes $1M Stock Repurchase Program

<p><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1731348/000143774925021037/tlry20250621_8k.htm" title="https://www.sec.gov/ix?doc=/Archives/edgar/data/1731348/000143774925021037/tlry20250621_8k.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/1731348/000143774925021037/tlry20250621_8k.htm</a></p>


TLRY

Tilray Brands Enters Into Private Debt-For Equity Exchange Transaction With Unrelated Party; Company Issued 12,591,816 Shares In Exchange For $5M Principal Amount Of Its 5.20% Convertible Senior Notes Due June 1, 2027

THOR Industries Announces Re-Authorization of $400M Share Buyback

<p>Brookfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BN#NYSE">BN</a>) has outperformed the market over the past 20 years by 3.66% on an annualized basis producing an average annual return of 12.08%. Currently, Brookfield has a market capitalization of $90.25 billion. </p>
<p><strong>Buying $100 In BN:</strong> If an investor had bought $100 of BN stock 20 years ago, it would be worth <strong>$976.79</strong> today based on a price of $58.84 for BN at the time of writing.</p>
<h3>Brookfield's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750709758_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

$100 Invested In Brookfield 20 Years Ago Would Be Worth This Much Today

DHI Group Announces Organizational Restructuring And Will Reduce Workforce By About 25% With Restructuring Expected To Generate $14M-$16M Annual Cost Savings

KB Home shares are trading lower following Q2 financial results.

<p><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001988776/000114036125023345/ny20050503x3_f1.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/0001988776/000114036125023345/ny20050503x3_f1.htm</a></p>


MRNO

Murano Global Investments Files Prospectus For Offer & Sale Of Up To 129.8M Ordinary Shares By Selling Stockholders

<p>Deep-pocketed investors have adopted a bullish approach towards Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in EL usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Estee Lauder Cos. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 44% leaning bullish and 33% bearish. Among these notable options, 3 are puts, totaling $151,440, and 6 are calls, amounting to $363,515.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $130.0 for Estee Lauder Cos, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Estee Lauder Cos's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Estee Lauder Cos's whale trades within a strike price range from $60.0 to $130.0 in the last 30 days. </p>
<h3>Estee Lauder Cos Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750709512_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>EL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$15.45</td>
<td>$13.75</td>
<td>$15.45</td>
<td>$90.00</td>
<td>$100.4K</td>
<td>833</td>
<td align="right">66</td>
</tr>
<tr>
<td>EL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$80.00</td>
<td>$78.3K</td>
<td>163</td>
<td align="right">445</td>
</tr>
<tr>
<td>EL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$2.6</td>
<td>$2.08</td>
<td>$2.3</td>
<td>$130.00</td>
<td>$69.0K</td>
<td>205</td>
<td align="right">300</td>
</tr>
<tr>
<td>EL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.25</td>
<td>$2.83</td>
<td>$3.0</td>
<td>$60.00</td>
<td>$63.6K</td>
<td>3.8K</td>
<td align="right">214</td>
</tr>
<tr>
<td>EL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/18/26</td>
<td>$14.65</td>
<td>$14.6</td>
<td>$14.6</td>
<td>$80.00</td>
<td>$58.2K</td>
<td>3</td>
<td align="right">42</td>
</tr>
</tbody>
</table>
</p>
<h3>About Estee Lauder Cos</h3>
<p>Estée Lauder is a leader in the global prestige beauty market, participating across skin care (51% of fiscal 2024 sales), makeup (29%), fragrance (16%), and hair care (4%) categories, with top-selling brands such as Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 30% of revenue from the Americas, 39% from Europe, the Middle East and Africa (including travel retail), and 31% from Asia-Pacific. Estée Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.</p>
<p>In light of the recent options history for Estee Lauder Cos, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Estee Lauder Cos</h3>
<ul>
<li>Currently trading with a volume of 5,618,734, the EL's price is up by 2.9%, now at $77.37. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 58 days.</li>
</ul>
<h3>What Analysts Are Saying About Estee Lauder Cos</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $79.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Estee Lauder Cos with a target price of $63.<br />
&#x2A; In a positive move, an analyst from Deutsche Bank has upgraded their rating to Buy and adjusted the price target to $95. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Estee Lauder Cos, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

This Is What Whales Are Betting On Estee Lauder Cos

<p>Financial giants have made a conspicuous bearish move on Qualcomm. Our analysis of options history for Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) revealed 15 unusual trades.</p>
<p>Delving into the details, we found 40% of traders were bullish, while 53% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $578,284, and 8 were calls, valued at $1,126,501.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $75.0 to $200.0 for Qualcomm over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Qualcomm's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Qualcomm's whale activity within a strike price range from $75.0 to $200.0 in the last 30 days. </p>
<h3>Qualcomm Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750709507_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$23.45</td>
<td>$22.4</td>
<td>$23.35</td>
<td>$150.00</td>
<td>$471.5K</td>
<td>373</td>
<td>2.0K</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$13.1</td>
<td>$10.85</td>
<td>$11.18</td>
<td>$200.00</td>
<td>$447.2K</td>
<td>1.7K</td>
<td>400</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$12.8</td>
<td>$12.7</td>
<td>$12.8</td>
<td>$150.00</td>
<td>$160.4K</td>
<td>2.5K</td>
<td>39</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.5</td>
<td>$8.4</td>
<td>$8.4</td>
<td>$135.00</td>
<td>$147.0K</td>
<td>2.9K</td>
<td>196</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$32.8</td>
<td>$32.5</td>
<td>$32.8</td>
<td>$180.00</td>
<td>$82.0K</td>
<td>1.6K</td>
<td>25</td>
</tr>
</tbody>
</table>
</p>
<h3>About Qualcomm</h3>
<p>Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.</p>
<h3>Qualcomm's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,016,615, the price of QCOM is up by 0.93%, reaching $152.72.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 37 days from now.</li>
</ul>
<h3>Expert Opinions on Qualcomm</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $200.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Qualcomm with a target price of $200. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Qualcomm options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


QCOM

What the Options Market Tells Us About Qualcomm

<p><strong>Zhengye Biotechnology Holding </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares are trading lower after the company announced it received a <a href="https://www.benzinga.com//node/45595426">Nasdaq noncompliance notice</a>.</p>
<p><strong>What To Know: </strong>Zhengye said it received a letter from the Nasdaq Stock Market on May 20, stating that it is not in compliance with listing rules due to its failure to timely file its annual report for the fiscal year ended Dec. 31, 2024.</p>
<p>The company has 60 calendar days from the date of the notice to submit a plan to regain compliance. If Nasdaq accepts the plan, Zhengye may be granted an extension of up to 180 days, or until Nov. 11 to file the report.</p>
<p>The company said the notice has no immediate effect on the listing of its ordinary shares on the Nasdaq Capital Market.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/46060153/analyst-flags-septerna-as-undervalued-biotech-play-with-significant-upside">Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside</a></strong></p>
<p><strong>ZYBT Price Action:</strong> At publication on Monday, Zhengye shares are trading 20.16% lower at $7.43, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwi-xZfImYiOAxXWnokEHTNOBS8QFnoECAsQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.</p>
<p><em>Image: This illustration was generated using artificial intelligence via Midjourney.<br /></em></p>


Movers

ZYBT

Zhengye Biotechnology Stock Is Trading Lower On Monday: What's Going On?

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Cleanspark</strong>.</p>
<p>Looking at options history for Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) we detected 11 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 72% of the investors opened trades with bullish expectations and 27% with bearish.</p>
<p>From the overall spotted trades, 8 are puts, for a total amount of $566,660 and 3, calls, for a total amount of $103,719.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $9.0 to $15.0 for Cleanspark during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Cleanspark options trades today is 1387.0 with a total volume of 6,970.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Cleanspark's big money trades within a strike price range of $9.0 to $15.0 over the last 30 days.</p>
<h3>Cleanspark Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750709502_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$3.95</td>
<td>$3.85</td>
<td>$3.85</td>
<td>$12.00</td>
<td>$115.5K</td>
<td>3.0K</td>
<td align="right">300</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$3.35</td>
<td>$3.25</td>
<td>$3.25</td>
<td>$11.00</td>
<td>$97.5K</td>
<td>411</td>
<td align="right">600</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$3.35</td>
<td>$3.25</td>
<td>$3.25</td>
<td>$11.00</td>
<td>$97.5K</td>
<td>411</td>
<td align="right">300</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/01/25</td>
<td>$5.7</td>
<td>$5.35</td>
<td>$5.39</td>
<td>$14.00</td>
<td>$67.5K</td>
<td>246</td>
<td align="right">251</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/01/25</td>
<td>$5.6</td>
<td>$5.35</td>
<td>$5.4</td>
<td>$14.00</td>
<td>$67.5K</td>
<td>246</td>
<td align="right">125</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cleanspark</h3>
<p>Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.</p>
<p>Following our analysis of the options activities associated with Cleanspark, we pivot to a closer look at the company's own performance.</p>
<h3>Cleanspark's Current Market Status</h3>
<ul>
<li>With a trading volume of 26,859,825, the price of CLSK is down by -2.06%, reaching $8.81.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 45 days from now.</li>
</ul>
<h3>What The Experts Say On Cleanspark</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $14.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Cleanspark, maintaining a target price of $14. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Cleanspark, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


CLSK

Market Whales and Their Recent Bets on CLSK Options

Legal

Press Releases

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Registration Is Now Open For Tribe Public's Webinar Event "Keys To The Kingdom: Unlocking The Power Of Your Immune System" Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Earnings

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Health Care

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Analyst Ratings

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

INDP

Apollomics Inc. - Class A Ordinary Shares

Apollomics

180 Life Sciences

Azitra

Bone Biologics

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

Galecto

GRI Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mustang Bio

Moleculin Biotech

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Mainz Biomed

Polyrizon

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

SILO Pharma

Soligenix

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tharimmune

Theriva Biologics

VivoSim Labs

Xenetic Biosciences

Maxim Group

HC Wainwright & Co.

Screenshot 2025-05-27 at 5.38.59 PM

Reiteration

Indaptus Therapeutics Q1 Update: Company Advances Decoy20 Immunotherapy To Fight Cancer, Maxim Group Analyst Reiterates Buy Rating

Screenshot 2025-04-21 at 5.37.26 PM

Bacteria: The Surprising Tool In The Fight Against Cancer – And How Indaptus Is Taking It Further

Screenshot 2025-03-17 at 5.34.34 PM

Aggressive Cancers In Young People Are On The Rise – Can The Immune System Fight Back Better? Indaptus Therapeutics Thinks So

Comments

Indaptus Therapeutics

Noticias

Últimas noticias sobre Indaptus Therapeutics (NASDAQ:INDP) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL